185 related articles for article (PubMed ID: 26646960)
21. [Time interval between ovarian cancer surgery and chemotherapy--secondary publication?].
Larsen EP; Blaakaer J
Ugeskr Laeger; 2009 Nov; 171(45):3265-8. PubMed ID: 19916194
[TBL] [Abstract][Full Text] [Related]
22. [PARP INHIBITORS FOR ADJUVANT TREATMENT FOR OVARIAN CANCER].
Marom I; Lavie O; Ostrovsky L; Kugelman N; Schmidt M; Segev Y
Harefuah; 2020 Mar; 159(3):175-180. PubMed ID: 32186787
[TBL] [Abstract][Full Text] [Related]
23. Conservative treatment in epithelial ovarian cancer: results of a multicentre study of the GCCLCC (Groupe des Chirurgiens de Centre de Lutte Contre le Cancer) and SFOG (Société Francaise d'Oncologie Gynécologique).
Morice P; Leblanc E; Rey A; Baron M; Querleu D; Blanchot J; Duvillard P; Lhommé C; Castaigne D; Classe JM; Bonnier P;
Hum Reprod; 2005 May; 20(5):1379-85. PubMed ID: 15817592
[TBL] [Abstract][Full Text] [Related]
24. Cytogenetic analysis of carboplatin resistance in early-stage epithelial ovarian carcinoma.
Osterberg L; Levan K; Partheen K; Helou K; Horvath G
Cancer Genet Cytogenet; 2005 Dec; 163(2):144-50. PubMed ID: 16337857
[TBL] [Abstract][Full Text] [Related]
25. Olaparib: a review of its use as maintenance therapy in patients with ovarian cancer.
Frampton JE
BioDrugs; 2015 Apr; 29(2):143-50. PubMed ID: 25899311
[TBL] [Abstract][Full Text] [Related]
26. An overview of early investigational therapies for chemoresistant ovarian cancer.
Marchetti C; Ledermann JA; Benedetti Panici P
Expert Opin Investig Drugs; 2015; 24(9):1163-83. PubMed ID: 26206420
[TBL] [Abstract][Full Text] [Related]
27. Epithelial ovarian cancer treated by platinum or platinum analogue with cyclophosphamide: experience in Ramathibodi Hospital.
Linasmita V; Wilailak S; Srisupundit S; Tangtrakul S; Bullangpoti S; Israngura N
J Med Assoc Thai; 1998 Jan; 81(1):10-6. PubMed ID: 9470316
[TBL] [Abstract][Full Text] [Related]
28. New advances in ovarian cancer.
Liu J; Matulonis UA
Oncology (Williston Park); 2010 Jul; 24(8):721-8. PubMed ID: 20718251
[TBL] [Abstract][Full Text] [Related]
29. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study.
Burger RA; Sill MW; Monk BJ; Greer BE; Sorosky JI
J Clin Oncol; 2007 Nov; 25(33):5165-71. PubMed ID: 18024863
[TBL] [Abstract][Full Text] [Related]
30. Advances in the management of epithelial ovarian cancer.
Berkenblit A; Cannistra SA
J Reprod Med; 2005 Jun; 50(6):426-38. PubMed ID: 16050567
[TBL] [Abstract][Full Text] [Related]
31. Clinical trials and future potential of targeted therapy for ovarian cancer.
Itamochi H; Kigawa J
Int J Clin Oncol; 2012 Oct; 17(5):430-40. PubMed ID: 22926640
[TBL] [Abstract][Full Text] [Related]
32. [Current post-surgical treatment strategies in first-line ovarian cancer].
Ouali K; Michels J; Blanc-Durand F; Leary A; Kfoury M; Genestie C; Morice P; Zaccarini F; Scherrier S; Gouy S; Maulard A; Pautier P
Bull Cancer; 2024 Mar; 111(3):267-276. PubMed ID: 36863923
[TBL] [Abstract][Full Text] [Related]
33. [Treatment strategies in ovarian cancer].
Puistola U; Leminen A
Duodecim; 2013; 129(18):1917-24. PubMed ID: 24187783
[TBL] [Abstract][Full Text] [Related]
34. The systemic treatment of recurrent ovarian cancer revisited.
Baert T; Ferrero A; Sehouli J; O'Donnell DM; González-Martín A; Joly F; van der Velden J; Blecharz P; Tan DSP; Querleu D; Colombo N; du Bois A; Ledermann JA
Ann Oncol; 2021 Jun; 32(6):710-725. PubMed ID: 33675937
[TBL] [Abstract][Full Text] [Related]
35. Maintenance therapy in epithelial ovarian cancer: from chemotherapy to targeted agents.
Falci C; Dieci MV; Guarneri V; Soldà C; Bria E; Tortora G; Conte P
Expert Rev Anticancer Ther; 2014 Sep; 14(9):1041-50. PubMed ID: 24953376
[TBL] [Abstract][Full Text] [Related]
36. Epithelial ovarian cancer: Does the time interval between primary surgery and postoperative chemotherapy have any prognostic importance?
Larsen E; Blaakaer J
Acta Obstet Gynecol Scand; 2009; 88(4):373-7. PubMed ID: 19253061
[TBL] [Abstract][Full Text] [Related]
37. Relationship between time interval from primary surgery to the start of taxane- plus platinum-based chemotherapy and clinical outcome of patients with advanced epithelial ovarian cancer: results of a multicenter retrospective Italian study.
Gadducci A; Sartori E; Landoni F; Zola P; Maggino T; Maggioni A; Cosio S; Frassi E; LaPresa MT; Fuso L; Cristofani R
J Clin Oncol; 2005 Feb; 23(4):751-8. PubMed ID: 15613698
[TBL] [Abstract][Full Text] [Related]
38. Neoadjuvant chemotherapy followed by interval cytoreductive surgery in patients with unresectable, advanced stage epithelial ovarian cancer: a single centre experience.
Bilici A; Salepci T; Dane F; Gumus M; Ustaalioglu BB; Seker M; Salman T; Turan C; Unal O; Yaylaci M
Arch Gynecol Obstet; 2010 Oct; 282(4):417-25. PubMed ID: 20035339
[TBL] [Abstract][Full Text] [Related]
39. Veliparib for the treatment of ovarian cancer.
Bogliolo S; Cassani C; Dominoni M; Musacchi V; Venturini PL; Spinillo A; Ferrero S; Gardella B
Expert Opin Investig Drugs; 2016; 25(3):367-74. PubMed ID: 26807493
[TBL] [Abstract][Full Text] [Related]
40. The role of niraparib for the treatment of ovarian cancer.
Ethier JL; Lheureux S; Oza AM
Future Oncol; 2018 Oct; 14(25):2565-2577. PubMed ID: 29856239
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
